Hepatitis C: Update on management of chronic infection

Journal of Clinical Outcomes Management

Volumn 11, Issue 8, 2004, Pages 523-533

  Reddy, Sarathchandra I ^a   Ukomadu, Chinweike ^a  

^a BRIGHAM AND WOMEN S HOSPITAL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

INTERFERON; PEGINTERFERON; PEGINTERFERON ALPHA2A; PEGINTERFERON ALPHA2B; RIBAVIRIN; VIRUS RNA;

ABDOMINAL PAIN; ADULT; ALCOHOL CONSUMPTION; ALOPECIA; ANEMIA; ANOREXIA; ANXIETY DISORDER; ARTHRALGIA; BEHAVIOR MODIFICATION; BODY WEIGHT DISORDER; CASE REPORT; COMPREHENSION; DECISION MAKING; DEPRESSION; DIARRHEA; DISEASE COURSE; DYSPEPSIA; FATIGUE; FEVER; FLU LIKE SYNDROME; HEADACHE; HEPATITIS C; HUMAN; HYPOTHYROIDISM; INFECTION RISK; INJECTION SITE REACTION; INSOMNIA; INTRAVENOUS DRUG ABUSE; IRRITABILITY; LEUKOPENIA; LIVER BIOPSY; LIVER FAILURE; MALE; MONOTHERAPY; MYALGIA; NAUSEA; NEUTROPENIA; OBESITY; PATIENT CARE; PATIENT EDUCATION; PERSONALITY DISORDER; RASH; REVIEW; SEXUAL BEHAVIOR; SIDE EFFECT; THROMBOCYTOPENIA; VIRUS TRANSMISSION; WEIGHT REDUCTION;

EID: 4644247254     PISSN: 10796533     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (47)

1. Pratt DS, Kaplan MM. Evaluation of abnormal liver-enzyme results in asymptomatic patients. N Engl J Med 2000;342: 1266-71.
2. Alter MJ, Kruszon-Moran D, Nainan OV, et al. The prevalence of hepatitis C virus infection in the United States, 1988 through 1994. N Engl J Med 1999;341:556-62.
3. Seeff LB, Hooffnagle JH. Appendix: the National Institutes of Health Consensus Development Conference. Management of hepatitis C 2002. Clin Liver Dis 2003;7:261-87.
4. Seeff LB, Hooffnagle JH. National Institutes of Health Consensus Development Conference: management of hepatitis C: 2002. Hepatology 2002;36(5 Suppl 1):S1-2.
5. Thomas DL, Villano SA, Riester KA, et al. Perinatal transmission of hepatitis C virus from human immunodeficiency virus type 1-infected mothers. Women and Infants Transmission Study. J Infect Dis 1998;177:1480-8.
6. Ohto H, Terazawa S, Sasaki N, et al. Transmission of hepatitis C virus from mothers to infants. The Vertical Transmission of Hepatitis C Virus Collaborative Study Group. N Engl J Med 1994;330:744-50.
7. Terrault NA. Sexual activity as a risk factor for hepatitis C. Hepatology 2002;36(5 Suppl 1):S99-105.
8. Vandelli C, Renzo F, Romano L, et al. Lack of evidence of sexual transmission of hepatitis C among monogamous couples: results of a 10-year prospective follow-up study. Am J Gastroenterol 2004;99:855-9.
9. Lauer GM, Walker BD. Hepatitis C virus infection. N Engl J Med 2001;345:41-52.
10. Poynard T, Bedossa P, Opolon P. Natural history of liver fibrosis progression in patients with chronic hepatitis C. The OBSVIRC, METAVIR, CLINIVIR, and DOSVIRC groups. Lancet 1997;349:825-32.
11. Tong MJ, el-Farra NS, Reikes AR, Co RL. Clinical outcomes after transfusion-associated hepatitis C. N Engl J Med 1995; 332:1463-6.
12. Kenny-Walsh E. Clinical outcomes after hepatitis C infection from contaminated anti-D immune globulin. Irish Hepatology Research Group. N Engl J Med 1999;340:1228-33.
13. Sanchez-Quijano A, Andreu J, Gavilan F, et al. Influence of human immunodeficiency virus type 1 infection on the natural course of chronic parenterally acquired hepatitis C. Eur J Clin Microbiol Infect Dis 1995;14:949-53.
14. Zarski JP, Bohn B, Bastie A, et al. Characteristics of patients with dual infection by hepatitis B and C viruses. J Hepatol 1998;28:27-33.
15. Wiley TE, Brown J, Chan J. Hepatitis C infection in African Americans: its natural history and histological progression. Am J Gastroenterol 2002;97:700-6.
16. Manns MP, McHutchison JG, Gordon SC, et al. Peginterferon alfa-2b plus ribavirin compared with interferon alfa-2b plus ribavirin for initial treatment of chronic hepatitis C: a randomised trial. Lancet 2001;358:958-65.
17. Fried MW, Shiffman ML, Reddy KR, et al. Peginterferon alfa-2a plus ribavirin for chronic hepatitis C virus infection. N Engl J Med 2002;347:975-82.
18. Hadziyannis SJ, Sette H Jr, Morgan TR, et al. Peginterferon-alpha2a and ribavirin combination therapy in chronic hepatitis C: a randomized study of treatment duration and ribavirin dose. Ann Intern Med 2004;140:346-55.
19. Marcellin P, Levy S, Erlinger S. Therapy of hepatitis C: patients with normal aminotransferase levels. Hepatology 1997; 26(3 Suppl 1):133S-136S.
20. Gebo KA, Herlong HF, Torbenson MS, et al. Role of liver biopsy in management of chronic hepatitis C: a systematic review. Hepatology 2002;36(5 Suppl 1):S161-72.
21. Bacon BR. Treatment of patients with hepatitis C and normal serum aminotransferase levels. Hepatology 2002;36(5 Suppl 1): S179-84.
22. Cicardi M, Cesana B, Del Ninno E, et al. Prevalence and risk factors for the presence of serum cryoglobulins in patients with chronic hepatitis C. J Viral Hepat 2000;7:138-43.
23. Cacoub P, Renou C, Rosenthal E, et al. Extrahepatic manifestations associated with hepatitis C virus infection. A prospective multicenter study of 321 patients. The GERMIVIC. Groupe d'Etude et de Recherche en Medecine Interne et Maladies Infectieuses sur le Virus de l'Hepatite C. Medicine (Baltimore) 2000;79:47-56.
24. Gumber SC, Chopra S. Hepatitis C: a multifaceted disease. Review of extrahepatic manifestations. Ann Intern Med 1995; 123:615-20.
25. Herrero C, Vicente A, Bruguera M, et al. Is hepatitis C virus infection a trigger of porphyria cutanea tarda? Lancet 1993; 341:788-9.
26. Silvestri F, Baccarani M. Hepatitis C virus-related lymphomas. Br J Haematol 1997;99:475-80.
27. Di Bisceglie AM, Martin P, Kassianides C, et al. Recombinant interferon alfa therapy for chronic hepatitis C. A randomized, double-blind, placebo-controlled trial. N Engl J Med 1989; 321:1506-10.
28. Davis GL, Balart LA, Schiff ER, et al. Treatment of chronic hepatitis C with recombinant interferon alfa. A multicenter randomized, controlled trial. Hepatitis Interventional Therapy Group. N Engl J Med 1989;321:1501-6.
29. McHutchison JG, Fried MW. Current therapy for hepatitis C: pegylated interferon and ribavirin. Clin Liver Dis 2003;7:149-61.
30. Zeuzem S, Feinman SV, Rasenack J, et al. Peginterferon alfa-2a in patients with chronic hepatitis C. N Engl J Med 2000; 343:1666-72.
31. Conry-Cantilena C, VanRaden M, Gibble J, et al. Routes of infection, viremia, and liver disease in blood donors found to have hepatitis C virus infection. N Engl J Med 1996;334:1691-6.
32. Heathcote EJ, Shiffman ML, Cooksley WG, et al. Peginterferon alfa-2a in patients with chronic hepatitis C and cirrhosis. N Engl J Med 2000;343:1673-80.
33. Wright TL. Treatment of patients with hepatitis C and cirrhosis. Hepatology 2002;36(5 Suppl 1):S185-94.
34. Shiratori Y, Imazeki F, Moriyama M, et al. Histologic improvement of fibrosis in patients with hepatitis C who have sustained response to interferon therapy. Ann Intern Med 2000;132:517-24.
35. Poynard T, McHutchison J, Manns M, et al. Impact of pegylated interferon alfa-2b and ribavirin on liver fibrosis in patients with chronic hepatitis C. Gastroenterology 2002;122: 1303-13.
36. Van Vlierbergh H, Delanghe JR, De Vos M; et al. BASL Steering Committee. Factors influencing ribavirin-induced hemolysis. J Hepatol 2001;34:911-6.
37. Van Thiel DH, Faruki H, Friedlander L, et al. Combination treatment of advanced HCV associated liver disease with interferon and G-CSF. Hepatogastroenterology 1995;42:907-12.
38. Dieterich DT, Wasserman R, Brau N, et al. Once-weekly epoetin alfa improves anemia and facilitates maintenance of ribavirin dosing in hepatitis C virus-infected patients receiving ribavirin plus interferon alfa. Am J Gastroenterol 2003; 98:2491-9.
39. Dusheiko GM, Roberts JA. Treatment of chronic type B and C hepatitis with interferon alfa: an economic appraisal. Hepatology 1995;22:1863-73.
40. Wong JB, Bennett WG, Koff RS, Pauker SG. Pretreatment evaluation of chronic hepatitis C: risks, benefits, and costs. JAMA 1998;280:2088-93.
41. Bennett WG, Inoue Y, Beck JR, et al. Estimates of the cost-effectiveness of a single course of interferon-alpha 2b in patients with histologically mild chronic hepatitis C. Ann Intern Med 1997;127:855-65.
42. Kim WR, Poterucha JJ, Hermans JE, et al. Cost-effectiveness of 6 and 12 months of interferon-alpha therapy for chronic hepatitis C. Ann Intern Med 1997;127:866-74.
43. Salomon JA, Weinstein MC, Hammitt JK, Goldie SJ. Cost-effectiveness of treatment for chronic hepatitis C infection in an evolving patient population. JAMA 2003;290:228-37.
44. Sagmeister M, Wong JB, Mullhaupt B, Renner EL. A pragmatic and cost-effective strategy of a combination therapy of interferon alpha-2b and ribavirin for the treatment of chronic hepatitis C. Eur J Gastroenterol Hepatol 2001;13:483-8.
45. Younossi ZM, Singer ME, McHutchison JG, Shermock KM. Cost effectiveness of interferon alpha2b combined with ribavirin for the treatment of chronic hepatitis C. Hepatology 1999;30:1318-24.
46. Stein K, Rosenberg W, Wong J. Cost effectiveness of combination therapy for hepatitis C: a decision analytic model. Gut 2002;50:253-8.
47. Wong JB, Nevens F. Cost-effectiveness of peginterferon alfa-2b plus ribavirin compared to interferon alfa-2b plus ribavirin as initial treatment of chronic hepatitis C in Belgium. Acta Gastroenterol Belg 2002;65:110-11.